ECSP045368A - "antagonistas de los receptores de trombina" - Google Patents

"antagonistas de los receptores de trombina"

Info

Publication number
ECSP045368A
ECSP045368A EC2004005368A ECSP045368A ECSP045368A EC SP045368 A ECSP045368 A EC SP045368A EC 2004005368 A EC2004005368 A EC 2004005368A EC SP045368 A ECSP045368 A EC SP045368A EC SP045368 A ECSP045368 A EC SP045368A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
cycloalkyl
bond
ring
thrombine
Prior art date
Application number
EC2004005368A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045368(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045368A publication Critical patent/ECSP045368A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen tricíclicos sustituidos con heterocíclicos de la fórmulas su sal farmacéuticamente aceptable, en donde la línea punteada representa un enlace simple opcional; _____ - - - - - representa un enlace doble opcional; n es 0-2; Q es cicloalquilo, opcionalmente sustituido por R13 y R14; R13 y R14 se seleccionan independientemente entre alqluilo(C1-C6),cicloalquilo(C3-C8), -OH, alcoxi(C1-C6), R27 -arilalquilo(C1-C6), heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halógeno y haloalquilo; ó R13 y R14 forman en conjunto un anillo espirocíclico ó un anillo heterospirocíclico de 3-6 átomos; Het es un grupo heteroarilo opcionalmente sustituido mono- ó bicíclico; y B es un enlace, alquileno, ó alquenileno ó alquinileno opcionalmente sustituido, en donde los sustituyentes remanentes son como se definieron en la memoria descriptiva, como así también composiciones farmacéuticas que los contienen y un método para el tratamiento de enfermedades asociadas con trombosis, aterosclerosis, restenosis, hipertensión, angina pectoris, arritmia, insuficiencia cardiaca y cáncer administrando dichos compuestos. La terapia de combinación con otros agente cardiovasculares es también reivindicada.
EC2004005368A 2002-04-16 2004-10-15 "antagonistas de los receptores de trombina" ECSP045368A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
ECSP045368A true ECSP045368A (es) 2005-01-03

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005368A ECSP045368A (es) 2002-04-16 2004-10-15 "antagonistas de los receptores de trombina"

Country Status (33)

Country Link
US (3) US7304078B2 (es)
EP (5) EP2065384B1 (es)
JP (2) JP4558331B2 (es)
KR (1) KR101026929B1 (es)
CN (1) CN1659162B (es)
AR (1) AR039570A1 (es)
AT (3) ATE455774T1 (es)
AU (1) AU2003221932B2 (es)
BR (1) BRPI0309309B8 (es)
CA (1) CA2482858C (es)
CY (3) CY1107184T1 (es)
DE (3) DE60317493T3 (es)
DK (2) DK2065384T3 (es)
EC (1) ECSP045368A (es)
ES (3) ES2297150T7 (es)
FR (1) FR15C0047I2 (es)
IL (1) IL164585A (es)
LT (1) LTC1495018I2 (es)
LU (1) LU92759I2 (es)
MX (1) MXPA04010308A (es)
MY (1) MY144040A (es)
NL (1) NL300746I1 (es)
NO (2) NO330500B1 (es)
NZ (2) NZ535880A (es)
PE (1) PE20040412A1 (es)
PL (1) PL214718B1 (es)
PT (2) PT1495018E (es)
RU (2) RU2329264C9 (es)
SG (1) SG164279A1 (es)
SI (2) SI2065384T1 (es)
TW (1) TWI343919B (es)
WO (1) WO2003089428A1 (es)
ZA (1) ZA200408342B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
EP1751144B1 (en) * 2004-05-28 2008-08-27 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
CA2582353A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
PT1853592E (pt) * 2005-01-14 2011-05-10 Schering Corp S?ntese de an?logos da himbacina
JP2008526254A (ja) * 2005-01-14 2008-07-24 シェーリング コーポレイション ヒンバシン類似物のキラルプロパルギルアルコールおよびエステル中間体の調製
EP2399912B1 (en) * 2005-01-14 2015-02-25 Merck Sharp & Dohme Corp. An exo-selective synthesis of himbacine analogs
AR056919A1 (es) 2005-01-14 2007-11-07 Schering Corp SíNTESIS EXO- Y DIASTEREO- SELECTIVAS DE ANÁLOGOS DE HIMBACINA
EP1863778B1 (en) * 2005-03-31 2015-12-30 Merck Sharp & Dohme Corp. Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
US20070202140A1 (en) * 2005-12-22 2007-08-30 Veltri Enrico P Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
MX2008013246A (es) * 2006-04-13 2008-10-21 Schering Corp Antagonistas del receptor de trombina de anillo fusionado.
US8022088B2 (en) * 2006-06-29 2011-09-20 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008042422A2 (en) * 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
JP2010505836A (ja) * 2006-10-04 2010-02-25 シェーリング コーポレイション ヒンバシンの修飾された三環単位に基づいたトロンビン受容体アンタゴニスト
US20080194560A1 (en) * 2006-12-22 2008-08-14 Zhi Yun Wang Disintegration promoters in solid dose wet granulation formulations
WO2008118320A1 (en) * 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist
AU2009211888B2 (en) 2008-02-05 2013-06-20 Sanofi Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments
PL2240487T3 (pl) 2008-02-05 2012-05-31 Sanofi Sa Triazolopirydazyny jako inhibitory PAR1, ich otrzymywanie i zastosowanie jako leków
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
EP2805939B1 (en) 2008-05-19 2018-06-27 Merck Sharp & Dohme Corp. Heterocyclic compounds as factor IXA inhibitors.
WO2010141525A1 (en) * 2009-06-04 2010-12-09 Schering Corporation Active metabolite of a thrombin receptor antagonist
AU2010259003A1 (en) 2009-06-08 2011-11-10 Merck Sharp & Dohme Corp. A thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
PL2558462T3 (pl) 2010-04-16 2015-03-31 Sanofi Sa Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
WO2011128421A1 (de) 2010-04-16 2011-10-20 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
EP3024550A4 (en) * 2013-07-22 2016-12-07 Merck Sharp & Dohme CO-CRYSTAL FROM THE PAR-1 RECEPTOR ANTAGONIST VORAPAXAR AND ASPIRIN
WO2015026686A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
EP3035930A4 (en) * 2013-08-22 2017-03-08 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
EP3035929B1 (en) * 2013-08-22 2024-07-03 Merck Sharp & Dohme LLC 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
US20230312560A1 (en) 2020-07-22 2023-10-05 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
TW197435B (es) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
GB9102862D0 (en) * 1991-02-11 1991-03-27 Erba Carlo Spa N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
ES2219919T3 (es) * 1997-11-25 2004-12-01 Schering Corporation Antagonistas del receptor de trombina.
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
TWI302913B (en) 2000-06-15 2008-11-11 Schering Corp Thrombin receptor antagonists
JP4307260B2 (ja) 2001-10-18 2009-08-05 シェーリング コーポレイション トロンビンレセプタアンタゴニストとしてのヒンバシン類似物

Also Published As

Publication number Publication date
EP1860106B1 (en) 2010-01-20
NO2015016I2 (no) 2015-07-09
ES2357876T3 (es) 2011-05-03
DE60335679D1 (de) 2011-02-17
AR039570A1 (es) 2005-02-23
EP1982984A2 (en) 2008-10-22
TW200404068A (en) 2004-03-16
NO330500B1 (no) 2011-05-02
RU2329264C9 (ru) 2009-04-20
BRPI0309309B1 (pt) 2018-09-04
AU2003221932A1 (en) 2003-11-03
DE60317493T2 (de) 2008-09-18
NL300746I2 (es) 2016-01-21
EP1982984B1 (en) 2013-02-13
TWI343919B (en) 2011-06-21
NZ575139A (en) 2010-08-27
LU92759I2 (en) 2015-08-31
RU2004133375A (ru) 2005-07-10
CY2015029I2 (el) 2016-04-13
MXPA04010308A (es) 2005-02-03
EP1495018B1 (en) 2007-11-14
CY2015029I1 (el) 2016-04-13
US7304078B2 (en) 2007-12-04
ZA200408342B (en) 2006-05-31
DE60317493T3 (de) 2018-07-12
JP2005528406A (ja) 2005-09-22
KR20040099441A (ko) 2004-11-26
DK1495018T3 (da) 2008-02-18
DE60331114D1 (de) 2010-03-11
ES2297150T3 (es) 2008-05-01
PE20040412A1 (es) 2004-07-12
CY1111363T1 (el) 2015-08-05
BRPI0309309B8 (pt) 2021-05-25
PT2065384E (pt) 2011-03-16
US20030216437A1 (en) 2003-11-20
FR15C0047I2 (fr) 2016-05-06
SI1495018T1 (sl) 2008-04-30
PL373332A1 (en) 2005-08-22
FR15C0047I1 (es) 2015-08-28
RU2329264C2 (ru) 2008-07-20
JP4558331B2 (ja) 2010-10-06
RU2008106401A (ru) 2009-08-27
US20070270439A1 (en) 2007-11-22
EP1495018A1 (en) 2005-01-12
CY1107184T1 (el) 2012-10-24
ES2297150T7 (es) 2012-03-16
KR101026929B1 (ko) 2011-04-04
NO20044963L (no) 2004-11-15
BR0309309A (pt) 2005-02-15
NZ535880A (en) 2007-11-30
ATE455774T1 (de) 2010-02-15
CA2482858C (en) 2010-11-30
LTC1495018I2 (lt) 2017-04-10
WO2003089428A1 (en) 2003-10-30
AU2003221932B2 (en) 2007-11-22
ATE378330T1 (de) 2007-11-15
EP1982984A3 (en) 2008-10-29
CA2482858A1 (en) 2003-10-30
CN1659162A (zh) 2005-08-24
EP2062890A1 (en) 2009-05-27
EP2062890B1 (en) 2011-01-05
HK1123302A1 (en) 2009-06-12
PT1495018E (pt) 2008-02-19
EP1860106A1 (en) 2007-11-28
CN1659162B (zh) 2011-08-31
PL214718B1 (pl) 2013-09-30
US7713999B2 (en) 2010-05-11
ES2338171T3 (es) 2010-05-04
ATE494284T1 (de) 2011-01-15
EP2065384B1 (en) 2011-01-05
IL164585A0 (en) 2005-12-18
SI2065384T1 (sl) 2011-05-31
EP2065384A1 (en) 2009-06-03
NL300746I1 (es) 2016-01-21
IL164585A (en) 2010-11-30
JP2010132710A (ja) 2010-06-17
DK2065384T3 (da) 2011-05-02
SG164279A1 (en) 2010-09-29
DE60317493D1 (en) 2011-01-13
US20070179187A1 (en) 2007-08-02
MY144040A (en) 2011-07-29
NO2015016I1 (no) 2015-07-20
EP1495018B3 (en) 2011-03-16
HK1070887A1 (en) 2005-06-30
HK1129893A1 (en) 2009-12-11

Similar Documents

Publication Publication Date Title
ECSP045368A (es) "antagonistas de los receptores de trombina"
CO5570668A2 (es) Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
ES2092316T3 (es) Agentes antianginosos de purinona.
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
AR049696A1 (es) Derivados de indol
AR043998A1 (es) Acidos fenoxiaceticos
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
DE60303381D1 (de) Neue indolylpiperidin-derivate als potente antihistaminische und antiallergische mittel
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
ECSP077372A (es) Antagonistas del receptor de trombina
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR017189A1 (es) Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
AR035605A1 (es) Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR051334A1 (es) Derivados de 2- amido-4-feniltiazol
AR063095A1 (es) Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
AR061185A1 (es) Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
AR036092A1 (es) Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprende
AR035247A1 (es) Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen
AR042830A1 (es) Acidos carboxilicos y derivados utiles para el tratamiento y la prevencion de diabetes y dislipidemia; composiciones farmaceuticas y medicamentos.